Differential blood miRNA expression in brain amyloid imaging defined Alzheimer's disease and controls.

CURRENT STATUS: UNDER REVIEW

Helen Zong Ying Wu  helenwzy@hotmail.com
Centre for Healthy Brain Ageing
Corresponding Author
ORCiD: 0000-0003-2201-9848

Anbupalam Thalamuthu
University of New South Wales

Lesley Cheng
La Trobe University

Christopher Fowler
The Florey Institute of Neuroscience and Mental Health

Colin L Masters
The Florey Institute of Neuroscience and Mental Health

Perminder Sachdev
Centre for healthy brain ageing

Karen A. Mather
Centre for healthy brain ageing

DOI: 10.21203/rs.2.17624/v1

SUBJECT AREAS Neurobiology of Disease

KEYWORDS Alzheimer’s disease, biomarker, microRNA, amyloid imaging, early
diagnosis
Abstract

Background: Peripheral blood microRNAs (miRNA) have been identified as potential biomarkers for Alzheimer’s disease (AD). Study results have generally been inconsistent and limited by sample heterogeneity. The aim of this study is to establish candidate blood miRNA biomarkers for AD by comparing differences in miRNA expression between participants with brain amyloid imaging defined AD and normal cognition.

Methods: Blood RNA was extracted from a subset of participants from the Australian Imaging Biomarkers Lifestyle Study of Ageing cohort (AIBL) with brain amyloid imaging results. MiRNA profiling was performed using small RNA sequencing on 71 participants, comprising 40 AD with high brain amyloid burden on imaging (amyloid positive) and 31 cognitively normal controls with low brain amyloid burden (amyloid negative). Cross-sectional comparisons were made between groups to examine differential miRNA expression levels using Fisher’s exact tests. Replication of results was undertaken using a publicly available dataset of blood miRNA data of AD and controls. In silico analysis of downstream messenger RNA targets of candidate miRNAs was performed to elucidate potential biological function.

Results: After quality control, 816 miRNAs were available for analysis. There were 71 significantly differentially expressed miRNAs between the AD and control groups (p<0.05). Two of these miRNAs, miR-146b-5p and miR-15b-5p, were also significant in the replication cohort. Pathways analysis showed these miRNAs to be involved in innate immune system and regulation of the cell cycle respectively, both of which have relevance to AD pathogenesis.

Conclusion: Blood miR-146b-5p and miR15b-5p showed consistent differential
expression in AD compared to controls. Further replication and translational studies in strictly phenotyped cohorts are needed to establish their role as biomarkers for AD to have clinical utility.

**Background**

AD is a neurodegenerative disease characterised by deposition of amyloid β (Aβ) in neuritic plaques extracellularly and the intracellular formation of neurofibrillary tangles of hyperphosphorylated tau protein. It is a major source of disease burden worldwide, however currently there are no effective treatments. It is well recognised that AD is a biological and clinical continuum. It begins at a preclinical stage, and as molecular alterations and neurodegeneration accumulate, progress through to mild cognitive impairment due to AD (prodromal AD), towards mild, moderate, and severe dementia stages [1]. The National Institute on Aging and Alzheimer’s Association (NIA-AA) research framework defines AD biologically, by neuropathologic change or biomarkers [2]. Biomarkers are grouped into those of β amyloid deposition (e.g. through cerebrospinal fluid (CSF) measurements or positron-emission tomography (PET) imaging), pathologic tau, and neurodegeneration [AT(N)]. The relative high cost of PET and invasive nature of CSF sampling limit the accessibility and feasibility of these biomarkers for routine clinical use. Blood based biomarkers would offer great advantage as they are easily accessible and well tolerated in the clinical setting. Current blood biomarkers are limited and there is a need for the discovery of new blood-based biomarkers to enable early and accurate diagnosis of the disease. Alternatively, these less-invasive and less-expensive blood-based biomarkers may play a screening role in selecting individuals for more expensive/invasive testing [2] Furthermore, amyloid
and tau may explain only some aspects of AD pathophysiology, the discovery of new biomarkers could potentially lead to new insights into AD biology and therapeutic targets.

MicroRNAs (miRNAs) have been recognised as novel biomarkers of diseases because of their diverse tissue and cell specific biological and pathological functions [3]. They are a class of short non-coding RNA, of approximately 22 nucleotides in length, which in general post-transcriptionally downregulate protein expression. MiRNAs bind to complementary sites located in the three prime untranslated regions (3’ UTRs) of their target messenger RNAs (mRNAs) resulting in inhibition of translation [4, 5]. Their dysregulation has been implicated in various pathological conditions. Prior studies have proposed candidate miRNA biomarkers for AD, with differential expression of miRNAs in AD compared to control groups [6-8], however results of these biomarker studies have been inconsistent with a lack of reproducibility and validation of candidate miRNAs across studies. One constraint is the phenotypic variability across cohorts [6]. Most of the current studies define their cohorts based on clinical criteria. There is significant discordance between clinical diagnosis of AD with post-mortem examination for AD pathology [9]. Furthermore, individuals without cognitive impairment in the control cohort may harbour amyloid pathology at post-mortem. When searching for new biomarkers, it is important that cohort phenotypes are strictly defined, and the addition of brain amyloid imaging using positron emission tomography (PET) to identify Aβ burden in life improves the robustness of the diagnostic groups, especially when examining pre-clinical or early AD [2].

In this study, peripheral blood miRNA expression was examined in a well-phenotyped cohort with assessment of brain amyloid burden to support clinical
diagnosis of AD and a non-AD comparison group. Using small-RNA sequencing, differential miRNA expression among participants with amyloid positive AD compared to amyloid negative cognitively normal controls was assessed. Replication was undertaken in an independent cohort. The potential biological functions of candidate miRNAs and role in AD pathology were assessed using in silico analyses of mRNA targets and pathways.

Methods

Sample selection

This study is a cross sectional analysis of a subset of participants from the Australian Imaging Biomarkers Lifestyle Study of Ageing (AIBL) cohort. The methodology of recruitment for the AIBL study has been previously described [10]. AIBL is a longitudinal study involving participants with AD, mild cognitive impairment and healthy controls. A subset of the AIBL cohort underwent amyloid PET imaging at baseline and at 18-monthly intervals to measure brain Aβ burden [11]. Four different Aβ tracer compounds have been used in the AIBL cohort and participants were characterised as amyloid positive or negative based on tracer-specific standardised uptake value ratio (SUVR) defined by the AIBL research group using their CSIRO-developed CapAIBL PET quantification algorithm. The thresholds used were: PiB (SUVR 1.4), NAV4694 (SUVR 1.4), Flutemetamol (SUVR 0.55), and Florbetapir (SUVR 1.05) [12]. The thresholds were selected as per their association with risk of disease progression.

From the subset of the AIBL cohort with amyloid scans, participants were selected for our study if they met the following criteria:

PAXgene tubes of whole blood available for RNA extraction AND
Amyloid imaging data indicating high Aβ burden (amyloid positive) for the AD group OR
Amyloid imaging data indicating low Aβ burden (amyloid negative) for the non-AD cognitively normal control group

Additional criteria for the amyloid negative control group include:
A minimum of 36 months of cognitively normal diagnosis AND
A minimum of two amyloid negative scans (36 months follow-up) on PET imaging
Those who converted to MCI or AD during the follow-up period of up to 108 months were excluded.

The institutional ethics committees of Austin Health, St. Vincent’s Health, Hollywood Private Hospital, and Edith Cowan University granted ethics approval for the AIBL study. All volunteers gave written informed consent before participating in the study.

RNA extraction
Total RNA including miRNA was isolated using the PAXgene Blood miRNA Kit (Qiagen, Germany) following the manufacturer’s recommendations. RNA integrity was analysed using Bioanalyzer 2100 (Agilent, USA), and concentration and purity of total RNA (including miRNA) were quantified using the NanoDrop 2000 UV-spectrophotometer (Thermo Scientific, Wilmington, DE, USA). RNA samples were concentrated by Speedy vacuum to standardise samples to 60ng/ul followed by quality checks using the Xpose (Trinean) and TapeStation (Agilent). The amount of RNA used for the sequencing assay was 5µl (ie 300ng).

High throughput expression profiling of miRNAs
Library preparation and sequencing was performed by the Ramaciotti Centre for Genomics, University of New South Wales. Small RNA samples were converted to Illumina sequencing libraries using the QIAseq Small RNA -seq prep (Qiagen, Germany), following the manufacturer’s protocol. Libraries were normalised to 6nM and then pooled adding 26 libraries per pool. Each pool was sequenced using one NextSeq 500 1x75bp High Output flowcell and NextSeq 500/550 v2 kits, generating
75bp single end reads, with approximately 10 million reads per sample. A pass threshold of >85% of bases higher than Q30 was used. Fastq files were generated using bcl2fastq2.

The sRNAnalyzer pipeline [13] was used for pre-processing, alignment and summarising the read counts of the miRNA sequenced data. The quality of the raw sequenced data was initially examined using FastQC V0.11.5. The 5’ adapter: GTTCAGAGTTCTACAGTCCGACGATC, the 3’ adapter: AACTGTAGGCACCATCAAT and sequences below 15 nucleotides in length were removed in the pre-processing step. The Illumina TruSeq stop oligo sequences were also removed. sRNAnalyzer uses Cutadapt [14] to trim the adapter sequences and uses the software Prinseq [15] to remove low quality and short reads (nt <15). The quality of the pre-processed data was examined using the multiqc software [16]. The alignment module in sRNAnalyzer uses Bowtie [17] for alignment and provides choices for various miRNA and small RNA databases for mapping. For this study, miRBase (v21) and miRNA precursor annotations in MirGeneDB [18] with single read assignment option in which each read is counted only once to its first best alignment, were used. The alignment module uses a local probabilistic model to find best possible assignment of those reads that have multiple matches. The counts for individual mature or precursor miRNA were obtained using the summarisation module.

**Statistical methodology for differential expression analysis**

Sequencing count data were normalised and miRNAs with more than 30% missing observations were excluded. Additionally, very lowly expressed miRNAs (<5 for more than 10% of the samples) and those with very low average counts (<5) were excluded from the analysis. All the differential expression analyses including the normalisation of read counts and comparison of two groups were done using the
Bioconductor package edgeR [19]. Differential miRNA expression was examined between the amyloid positive AD and amyloid negative control groups using the Fisher’s exact test in edgeR. A p-value of <0.05 was considered nominally significant and because of the high number of tests performed, all p values were corrected for multiple testing. A false discovery rate (FDR) of <0.1 was considered significant for this study.

Replication of results in independent cohort

Replication of significantly differentiated miRNAs between AD and cognitively normal controls in the discovery AIBL cohort was performed in an independent sample with previously published miRNA data by Leidinger and colleagues [20]. The AD group fulfilled the NINCDS-ADRDA criteria for probable AD, but this study cohort was not biomarker defined with brain amyloid imaging. The raw small-RNA sequencing data from this cohort were downloaded as FASTQ-formatted files from the DDBJ Sequence Read Archive (DRA) (trace.ddbj.nig.ac.jp/DRASearch) under the accession number SRP022043. The data were processed using the same pipeline as this current study and differential miRNA expression analyses between AD and control groups performed as outlined above.

MiRNA target and biological function analyses

Candidate replicated miRNAs were assessed for putative target genes and pathways. Using Ingenuity® Pathway Analysis (IPA) (www.ingenuity.com), putative target genes were identified using the ‘microRNA Target Filter’ tool. Only target genes which were predicted in silico with high confidence and/or were experimentally validated were included. Gene-Enrichment/Functional Annotation analysis for the lists of mRNA targets was conducted using DAVID (the database for annotation, visualisation and integrated discovery;
functional annotation clustering was performed for each target mRNA gene list derived from each selected candidate miRNA (using IPA miRNA target filter tool described above). Relevant pathways using DAVID pathway viewer was accessed where applicable when there was an overrepresentation of genes in the selected lists in a relevant KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway [22].

Results

**AIBL cohort selection and demographics**
From the AIBL cohort, 80 participants (45 amyloid positive AD and 35 controls) had PAXgene tubes of whole blood available for RNA extraction. Following RNA extraction, 9 samples were excluded due to low RNA integrity number (RIN) of less than 6.5. Subsequently, 71 samples (40 AD and 31 controls) underwent miRNA profiling. The sample demographics are shown in Table 1. The mean age and standard deviation (SD) for the cohort (n=71) was 73.0 ± 6.3. The mean Mini-Mental State Examination (MMSE) [23] score for the AD group was 21.1 (SD 4.6), and for the control group 29.1 (SD 1.0). There was an overrepresentation of individuals with one or more APOE Ɛ4 alleles in the AD (80%) group, with the control group having only 32% positive for the presence of an APOE Ɛ4 allele.

| Sample group     | N   | Age (mean ± SD) | Sex (m/f) | MMSE (mean ± SD) | Amyloid PET status | APOE Ɛ4 carrier |
|------------------|-----|----------------|-----------|------------------|--------------------|-----------------|
| Whole cohort     | 71  | 73.0 ± 6.3     | 33/38     | 24.6 ± 5.3       | n/a                | n/a             |
| AD               | 40  | 74.9 ± 6.0     | 19/21     | 21.1 ± 4.6       | Positive           | 32 (80%)        |
| Controls         | 31  | 71.0 ± 5.9     | 14/17     | 29.1 ± 1.0       | Negative           | 10 (32%)        |

**Differential miRNA analysis: AD versus controls**

Following normalisation and quality control checks, 816 unique miRNAs were examined between individuals with amyloid positive AD and amyloid negative controls. There were 71 miRNAs differentially expressed between the two groups (p<0.05) and four of these remained significant after controlling for multiple testing (FDR <0.1). The 71 differentially expressed miRNAs are shown in Table 2. Of these, 43 miRNAs were upregulated and 28 were downregulated in AD compared to
controls. The top FDR significant miRNA (hsa-miR-218-1-5p) had a high fold change of 7.15. The magnitude of fold change for the remaining miRNAs ranged from 0.34 to 2.90.

Table 2: Dysregulated miRNAs between amyloid positive AD and amyloid negative cognitively normal controls

| miRNA            | Log$_2$ FC (AD vs controls) | Fold change$^a$ | p-value (unadj) | p-value (FDR-corr) |
|------------------|-----------------------------|-----------------|-----------------|-------------------|
| hsa-miR-218-1-5p | 2.84                        | 7.15            | 5.32E-08        | 4.34E-05          |
| hsa-miR-4482-3p  | -1.54                       | 0.34            | 8.79E-05        | 0.035865          |
| hsa-miR-16-2-3p  | 0.78                        | 1.72            | 0.000409        | 0.095074          |
| hsa-miR-4669-3p  | 1.30                        | 2.45            | 0.000466        | 0.095074          |
| hsa-let-7b-5p    | 0.75                        | 1.69            | 0.000771        | 0.125787          |
| hsa-miR-320a-3p  | 0.56                        | 1.47            | 0.001074        | 0.132259          |
| hsa-miR-574-5p   | 0.78                        | 1.71            | 0.001135        | 0.132259          |
| hsa-miR-5010-5p  | 0.72                        | 1.65            | 0.001754        | 0.178899          |
| hsa-miR-181a-1-5p| 0.46                        | 1.38            | 0.004002        | 0.277488          |
| hsa-miR-1306-3p  | 0.68                        | 1.60            | 0.004171        | 0.277488          |
| hsa-miR-320c-1-3p| 0.53                        | 1.45            | 0.004248        | 0.277488          |
| hsa-miR-3682-3p  | 0.68                        | 1.60            | 0.004318        | 0.277488          |
| hsa-miR-7113-5p  | 0.67                        | 1.59            | 0.004566        | 0.277488          |
| hsa-miR-30a-5p   | 0.67                        | 1.59            | 0.00476         | 0.277488          |
| hsa-miR-6793-3p  | 0.50                        | 1.41            | 0.005823        | 0.316788          |
| hsa-miR-3135a-5p | 0.60                        | 1.51            | 0.006553        | 0.328554          |
| hsa-miR-548ae-2-5p| 1.10                       | 2.14            | 0.007103        | 0.328554          |
| hsa-miR-3138     | -1.14                       | 0.45            | 0.007248        | 0.328554          |
| hsa-miR-6884-5p  | 0.58                        | 1.49            | 0.008981        | 0.385731          |
| hsa-miR-25-5p    | 0.44                        | 1.36            | 0.010531        | 0.404056          |
| hsa-miR-320b-1-3p| 0.43                        | 1.35            | 0.010797        | 0.404056          |
| hsa-miR-4772-3p  | -0.60                       | 0.66            | 0.011461        | 0.404056          |
| hsa-miR-3064-5p  | 0.56                        | 1.47            | 0.011532        | 0.404056          |
| hsa-miR-3607     | -0.53                       | 0.69            | 0.012026        | 0.404056          |
| hsa-miR-421-3p   | -0.25                       | 0.84            | 0.013088        | 0.404056          |
| hsa-miR-3922     | 0.50                        | 1.42            | 0.013536        | 0.404056          |
| hsa-miR-3605-5p  | 0.46                        | 1.37            | 0.014781        | 0.404056          |
| hsa-miR-4649-3p  | -0.53                       | 0.69            | 0.01502         | 0.404056          |
| hsa-miR-30a-3p   | 0.67                        | 1.59            | 0.015235        | 0.404056          |
| hsa-miR-542-3p   | 0.54                        | 1.46            | 0.015267        | 0.404056          |
| hsa-miR-4732-5p  | 0.42                        | 1.34            | 0.01535         | 0.404056          |
| hsa-miR-337-3p   | -0.51                       | 0.70            | 0.016418        | 0.412266          |
| hsa-miR-320d-1-3p| 0.47                        | 1.38            | 0.017108        | 0.412266          |
| hsa-miR-1273g    | 0.36                        | 1.29            | 0.017178        | 0.412266          |
| hsa-miR-3913-1-3p| -0.34                      | 0.79            | 0.018048        | 0.420787          |
| hsa-miR-3691-3p  | -0.35                       | 0.78            | 0.020256        | 0.459135          |
| hsa-miR-5701-1-5p| -0.57                       | 0.67            | 0.023849        | 0.475508          |
| hsa-miR-589-3p   | -0.26                       | 0.84            | 0.023928        | 0.475508          |
| hsa-mir-202      | -0.62                       | 0.65            | 0.02398         | 0.475508          |
| hsa-miR-23b-5p   | 0.33                        | 1.26            | 0.02412         | 0.475508          |
| hsa-miR-3138-3p  | 0.46                        | 1.38            | 0.024643        | 0.475508          |
| hsa-miR-641-5p   | -0.32                       | 0.80            | 0.025083        | 0.475508          |
| hsa-miR-15b-5p   | -0.25                       | 0.84            | 0.025333        | 0.475508          |
| hsa-mir-1248     | -0.62                       | 0.65            | 0.026133        | 0.475508          |
| hsa-miR-664b-5p  | 0.43                        | 1.34            | 0.026223        | 0.475508          |
| miRNA               | Log₂ FC (AD vs controls) | Fold change<sup>a</sup> | p-value (unadj) | p-value (FDR-corr) |
|---------------------|---------------------------|-------------------------|-----------------|--------------------|
| hsa-miR-579-5p      | 0.33                      | 1.26                    | 0.027033        | 0.479535           |
| hsa-miR-2277-3p     | 0.37                      | 1.29                    | 0.027747        | 0.481733           |
| hsa-miR-1287-5p     | 0.47                      | 1.38                    | 0.031054        | 0.525366           |
| hsa-miR-627-3p      | -0.29                     | 0.82                    | 0.032362        | 0.525366           |
| hsa-miR-423-5p      | 0.30                      | 1.23                    | 0.032829        | 0.525366           |
| hsa-miR-548n-3p     | -0.40                     | 0.76                    | 0.035717        | 0.541575           |
| hsa-miR-3607-3p     | -0.51                     | 0.70                    | 0.035911        | 0.541575           |
| hsa-miR-146b-5p     | -0.29                     | 0.82                    | 0.036279        | 0.541575           |
| hsa-miR-3667-5p     | 0.59                      | 1.50                    | 0.03858         | 0.541575           |
| hsa-miR-185-3p      | 0.31                      | 1.24                    | 0.038723        | 0.541575           |
| hsa-miR-10a-5p      | -0.41                     | 0.75                    | 0.039489        | 0.541575           |
| hsa-miR-628-5p      | -0.30                     | 0.81                    | 0.04009         | 0.541575           |
| hsa-miR-190a-5p     | 0.52                      | 1.44                    | 0.04149         | 0.541575           |
| hsa-miR-1284-5p     | -0.24                     | 0.84                    | 0.04199         | 0.541575           |
| hsa-let-7a-3        | 0.50                      | 1.41                    | 0.042166        | 0.541575           |
| hsa-miR-4742-3p     | -0.32                     | 0.80                    | 0.04264         | 0.541575           |
| hsa-miR-196a-1-5p   | 0.80                      | 1.74                    | 0.04283         | 0.541575           |
| hsa-miR-6513-3p     | -0.25                     | 0.84                    | 0.043181        | 0.541575           |
| hsa-miR-1294-5p     | 0.39                      | 1.31                    | 0.043499        | 0.541575           |
| hsa-miR-3130-1-5p   | -0.27                     | 0.83                    | 0.043804        | 0.541575           |
| hsa-miR-643-3p      | -0.38                     | 0.77                    | 0.04469         | 0.544284           |
| hsa-miR-6729-3p     | 0.40                      | 1.32                    | 0.045509        | 0.546106           |
| hsa-miR-1229        | 0.48                      | 1.40                    | 0.046396        | 0.548684           |
| hsa-miR-654-3p      | -0.46                     | 0.73                    | 0.048297        | 0.563006           |
| hsa-miR-128-1-3p    | -0.23                     | 0.85                    | 0.049922        | 0.565943           |

Log₂ FC = \log₂ \text{fold change}, \text{ directionality denoted by } + \text{ (upregulated)} \text{ or } - \text{ (downregulated) value when comparing AD to controls.} \text{ a Magnitude of fold change between AD compared to controls}

**Replication of dysregulated miRNAs in an independent cohort**

Using the same bioinformatics pipeline as the original analysis of differential blood miRNA expression in amyloid positive AD and amyloid negative controls, an independent blood miRNA-seq dataset derived from 48 AD and 22 cognitively normal control individuals was used to replicate the identified significant miRNAs shown in Table 2 [20]. This cohort comprised an AD group of 23 males and 25 females with average age 70.3 ± 7.9 years and MMSE score of 18.7 ± 3.5, as well as a normal control group of 11 males and 11 females with average age 67.1 ± 7.5 years and MMSE score 29.3 ± 1.2. In this cohort, 567 mature miRNAs were examined following data cleaning and normalisation using our bioinformatics pipeline. Of the 816 miRNAs examined in our AIBL cohort, 478 of these overlapped with miRNAs examined in the replication cohort.

In the replication cohort, of the original 71 differentially expressed miRNAs between AD and controls in the AIBL cohort, there were 34 miRNAs overlapping, of which only two miRNAs were significantly differentially expressed (p<0.05) and in the same
direction of dysregulation (Figure 1). MiR-15b-5p was downregulated in AD compared to controls in both the original cohort and in the replication cohort with fold change 0.84 and 0.78 (log2 fold change -0.25 and -0.35) respectively. Similarly, miR-146b-5p was downregulated in AD compared to controls with fold changes of 0.82 and 0.78 (log2 fold change -0.29 and -0.35) respectively.

**MiRNA target analysis**

Target mRNA information for miR-15b-5p and miR-146b-5p were sought bioinformatically (IPA). Results were filtered to include only experimentally validated or highly predicted targets. MiR-146b-5p had 158 mRNA targets fulfilling these criteria, and miR-15b-5p had 526 mRNA targets. To assess the biological function of these target mRNAs, gene enrichment functional annotation analysis using DAVID 6.8 was performed. Messenger RNA gene lists of miR-15b-5p and miR-146b-5p were uploaded for functional analysis. The results of the functional annotation analysis are summarised in Table 3, with the top annotation clusters with FDR significance listed. Messenger RNA targets of miR-146b-5p were centred around the innate immune system and cytokine pathways. MiR-15b-5p appears to target mRNAs involved in cell cycle and apoptosis. Pathways analysis (Table 4) showed the mRNAs targeted by miR-146b-5p to be involved in 28 KEGG pathways, of which 5 were significant (FDR <0.05). The top KEGG pathway was the Toll-like receptor signalling pathway, with 14 mRNAs (9.2%) of the target list involved. This is consistent with the results of annotation clustering as this pathway is critical to the innate response system. Messenger RNA targets of miR-15b-5p were also found to be significantly involved in KEGG pathways. These were found to be involved in 65 pathways, of which nine were statistically significant (FDR <0.05). Cancer pathways feature predominantly for miR-15b-5p, consistent with its annotation clustering of apoptosis and regulation of cell cycle.

**Table 3:** Functional annotation analysis of predicted gene targets of identified candidate miRNAs
### Functional annotation clustering analysis of target mRNA gene lists of candidate miRNAs using DAVID. Top annotation clusters are listed.

*Number of genes from the target mRNA gene list submitted for each miRNA (158 genes for miR-146b-5p and 526 genes for miR-15b-5p) that are involved in the annotation cluster.

| Candidate miRNA | Number of annotation clusters with enrichment score >1.3 for predicted gene targets | Annotation cluster                                                                 | Gene count* |
|-----------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------|
| miR-146b-5p     | 34                                                                                   | Innate immune response                                                            | 24          |
|                 |                                                                                        | Cellular response to cytokine stimulus                                            | 33          |
|                 |                                                                                        | Defence response to bacterium                                                     | 25          |
|                 |                                                                                        | Interleukin-1 receptor binding                                                    | 7           |
|                 |                                                                                        | Regulation of interleukin-6 production                                            | 13          |
|                 |                                                                                        | Regulation of interleukin-12 production                                           | 7           |
|                 |                                                                                        | Lipopolysaccharide-mediated signalling pathway                                    | 8           |
|                 |                                                                                        | Regulation of cytokine secretion                                                 | 10          |
| miR-15b-5p      | 31                                                                                   | Apoptotic process                                                                | 91          |
|                 |                                                                                        | Regulation of protein metabolic process                                          | 119         |
|                 |                                                                                        | Regulation of cell cycle                                                         | 36          |

**Table 4: Pathways analysis of predicted gene targets of identified candidate miRNAs**

| Candidate miRNA | Number of KEGG pathways for predicted gene targets | Top KEGG pathways                                                                 |
|-----------------|-----------------------------------------------------|-----------------------------------------------------------------------------------|
| miR-146b-5p     | 28                                                  | Toll-like receptor signalling pathway                                             |
|                 |                                                     | Chagas disease (American trypanosomiasis)                                       |
|                 |                                                     | Tuberculosis                                                                     |
|                 |                                                     | Cytokine-cytokine receptor interaction                                           |
|                 |                                                     | NF-kappa B signalling pathway                                                    |
| miR-15b-5p      | 65                                                  | Pathways in cancer                                                               |
|                 |                                                     | Melanoma                                                                         |
|                 |                                                     | PI3K-Akt signalling pathway                                                      |
|                 |                                                     | Prostate cancer                                                                  |
|                 |                                                     | FoxO signalling pathway                                                          |
|                 |                                                     | Acute myeloid leukemia                                                           |
|                 |                                                     | MiRNAs in cancer                                                                 |
|                 |                                                     | Progesterone-mediated oocyte maturation                                           |
|                 |                                                     | Glioma                                                                           |

Pathways analysis of target mRNA gene lists of candidate miRNAs using DAVID. Top KEGG pathways listed. *Number of genes from the target mRNA gene list submitted for each miRNA (158 genes for miR-146b-5p and 526 genes for miR-15b-5p) that are involved in the KEGG pathway (%).
Discussion

Prior studies seeking to identify miRNA blood biomarkers for AD have had inconsistent results, with most candidates lacking replication across independent cohorts. One factor contributing to the variation in results across studies is the different phenotypic definitions used to classify participant groups. This includes potential inclusion of controls that may have pre-clinical AD or the use of AD participants that may not have AD pathology. To minimise this issue in our study, participants were selected with the aid of brain amyloid burden data. This study, with the use of a cohort of amyloid imaging defined phenotypes in combination with robust longitudinal data, is one of the most strictly phenotyped AD biomarker studies to date.

_Differentially expressed miRNAs between AD and controls_

Using a non-hypothesis driven, 71 differentially expressed miRNAs were found between AD and controls. In a replication cohort, utilising a publicly available dataset and applying our bioinformatics pipeline, two of the original 71 differentially expressed miRNAs were replicated (miR–15b–5p, and miR–146b–5p). We propose these two miRNAs as candidate biomarkers for AD for further investigation. Indeed, there is already evidence from existing literature of their ability to differentiate AD from cognitively normal controls. MiR–15b–5p has been previously shown to be downregulated in blood of individuals with AD compared to controls, with a reported sensitivity of 0.85, specificity of 0.88, and area under the curve (AUC) of 0.96 in differentiating those with AD from controls [5]. In another study examining differential blood miRNA expression among discordant twins (n = 22 twin pairs) for dementia (including AD, vascular, or unspecified), miR–146b–5p was downregulated
in twins who were diagnosed with dementia [24]. Although this study was not specific for AD, the use of the discordant MZ twin model is a powerful tool for epigenetic studies as it controls for potential confounders encountered in case-control studies, such as differences in genetic factors, age, gender, maternal effects, and most in utero and early environmental influences.

**Message RNA targets and biological function analysis.**

To further our understanding of the biological function of the two candidate miRNA biomarkers and their potential role in AD pathology, *in silico* analysis of the target mRNAs of miR-146b–5p and miR-15b–5p was performed. Annotation clustering for miRNA-146b-5p gene targets were found to be centred around the innate immune system and cytokine production. This was further supported by the overrepresentation of those genes in the KEGG pathway for the Toll-like receptor signalling pathway, a crucial pathway involved in the innate immune response. Interestingly, in recent years, neuroinflammation has been recognised as an important component of AD pathology. Experimental, genetic and epidemiological evidence now indicate a crucial role for activation of the innate immune system as a disease-promoting factor [25]. Annotation clustering for miRNA-15b–5p gene targets, showed they are involved in apoptosis and regulation of the cell cycle. Pathway analysis of these mRNAs showed involvement in a number of cancer pathways. The relationship between cancer and AD has been of great interest to the research community. An inverse association between AD and cancer has been previously noted, with AD individuals developing cancer at a slower rate than the general population, and those with a history of cancer developing AD at a slower rate [26]. The pathomechanism is not clear, but it is postulated that in cancer, cell regulation mechanisms are disrupted with augmentation of cell survival or
proliferation, whereas conversely, AD is associated with increased neuronal death, driven by beta amyloid (Aβ) and tau deposition [27]. As discussed in a review by Holohan et al., a number of dysregulated miRNAs have been identified in both AD and cancer, suggesting that miRNAs play multiple regulatory roles in pathways active across both cancer and AD [28]. Interestingly, miR-15b-5p has been reported to promote gastric cancer metastasis and to be upregulated in gastric cancer cell lines, tissues and plasma samples [29]. In this AD cohort, miR-15b-5p was downregulated in AD compared to controls. Despite these postulations, future studies into the biological role of miRNAs will need further targeted experiments to confirm the validity and the biological significance of the identified in silico and experimental miRNA-mRNA interactions.

Limitations of study and future direction

This study has several limitations. Firstly, despite using the same bioinformatics pipeline, only two of the original 71 differentially expressed miRNAs were similarly dysregulated in the replication cohort. Reasons for this are largely attributable to the differences in study cohorts. The case control phenotypes in the current study were defined by amyloid imaging, whereas the replication cohort did not have amyloid biomarker support. There were further differences in disease severity and demographics of the two cohorts, including age (older in the present study) and MMSE (mean MMSE in replication AD sample being 18.9 (SD ± 3.4) compared to 21.1 (SD ± 4.6) in the present study).

Secondly, only one of the many bioinformatics methods available was used to analyse results (Edge-R). Indeed, it is well recognised that different statistical methods will result in different significant miRNAs. When the full results obtained in the replication cohort using our bioinformatics pipeline (data not shown) were
compared to the results published by the original investigators using their methodology, only 45 significant miRNAs overlapped. The discrepancy has also been demonstrated by Satoh and colleagues, who took the same publicly available dataset from Leidinger et al and processed the FASTQ files with a different bioinformatics pipeline [30]. Their pipeline yielded only 27 differentially expressed miRNAs between AD and controls, and of which only two were reported to be significant by the original investigators. There is an urgent need for consistency of data analysis across studies, however this is problematic as there are no best practice methods and consensus for the most appropriate method. Moreover, new methodology is continually being published, thus confounding the comparison of results across different studies.

Thirdly, our results were not experimentally validated using a different technology such as q-PCR, although replication in independent cohorts is a more robust approach to strengthening candidate miRNA biomarker findings, which was performed here using data from a previously published study. Finally, the expression of miRNA blood may not reflect the changes occurring in the target organ - the brain. Therefore, these differentially expressed miRNAs need further experimental validation to elucidate their role in pathobiology and effects at the target organ.

Conclusion

Two miRNAs identified in this study, miR–146b–5p and miR15b–5p, showed a consistent relative change in expression levels between AD and controls. Their biological function may also be related to AD pathogenesis. Further replication studies are needed to establish their role as biomarkers for AD, including
determining absolute value cut-offs and sensitivity/specificity analyses. To minimise
differences in methodologies confounding results when comparing across studies,
large consortia cohorts using a consensus approach are best positioned to drive
further translational studies. Experimental validation of mRNA targets and further
elucidation of the role these miRNAs play in biology may harbour insights into AD
pathogenesis and potential therapeutic targets.

List of Abbreviations

3’ UTR 3 prime untranslated region

AD Alzheimer’s disease

ADRA Alzheimer’s Disease and Related Disorders Association

AIBL Australian Imaging Biomarkers Lifestyle Study of Ageing

APOE apolipoprotein E

Aβ beta-amyloid

CSF cerebrospinal fluid

DAVID Database for Annotation, Visualisation and Integrated Discovery

DNA deoxyribonucleic acid

FC fold change

FDR false discovery rate

hsa homo sapiens

IPA Ingenuity Pathway Analysis

KEGG Kyoto Encyclopedia of Genes and Genomes

MCI mild cognitive impairment

miRNA microRNA

MMSE Mini-mental State Examination
Declarations

Ethics approval and consent to participate

The institutional ethics committees of Austin Health, St. Vincent’s Health, Hollywood Private Hospital, and Edith Cowan University granted ethics approval for the AIBL study. All volunteers gave written informed consent before participating in the study.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the
corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests

Funding
Dr Wu is supported by an NHMRC post-graduate scholarship.
The AIBL research project is supported by the Science and Industry Endowment Fund
The Roths Charitable Foundation supported the direct research costs associated with miRNA profiling

Authors' contributions
HW conceptualised the study and acquired, analysed, and interpreted the data, and wrote the manuscript. AT analysed and interpreted the data, LC was a major contributor to the design and concept of the study and acquired the data, CF was a major contributor to the design and concept of the study and acquired the data, CM was a major contributor to the design and concept of the study and acquired the data, PS was a major contributor to the design and concept of the study and interpreted the data and was a major contributor to the writing of the manuscript, KM was a major contributor to the design and concept of the study and interpreted the data and was a major contributor to the writing of the manuscript

Acknowledgements
Participants and researchers of the AIBL study from which samples for miRNA
profiling were collected. Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL). The AIBL study (www.AIBL.csiro.au) is a consortium between Austin Health, CSIRO, Edith Cowan University, the Florey Institute (The University of Melbourne), and the National Ageing Research Institute. The AIBL researchers contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at www.aibl.csiro.au.

References

1. Jack, C. R., Jr., et al., Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol, 2010. 9(1): p. 119–28.

2. Jack, C. R., Jr., et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & dementia: the journal of the Alzheimer’s Association, 2018. 14(4): p. 535–562.

3. Kroh, E. M., et al., Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods, 2010. 50(4): p. 298–301.

4. Cheng, L., et al., The detection of microRNA associated with Alzheimer’s disease in biological fluids using next-generation sequencing technologies. Front Genet, 2013. 4: p. 150.

5. Kumar, P., et al., Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One, 2013. 8(7): p. e69807.

6. Wu, H. Z., et al., Circulating microRNAs as Biomarkers of Alzheimer’s Disease: A Systematic Review. J Alzheimers Dis, 2015.

7. Kumar, S. and P. H. Reddy, Are circulating microRNAs peripheral biomarkers for
Alzheimer’s disease? Biochim Biophys Acta, 2016. 1862(9): p. 1617-27.

8.Kumar, S., et al., MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. Prog Mol Biol Transl Sci, 2017. 146: p. 47-94.

9.Nagy, Z., et al., Accuracy of clinical operational diagnostic criteria for Alzheimer’s disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Dispord, 1998. 9(4): p. 219-26.

10.Ellis, K. A., et al., The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr, 2009. 21(4): p. 672-87.

11.Pike, K. E., et al., Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain, 2007. 130(Pt 11): p. 2837-44.

12.Bourgeat, P., et al., Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging, 2015. 36 Suppl 1: p. S159-66.

13.Wu, X., et al., sRNAnalyzer-a flexible and customizable small RNA sequencing data analysis pipeline. Nucleic Acids Res, 2017. 45(21): p. 12140-12151.

14.Martin, M., Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011, 2011. 17(1): p. 3.

15.Schmieder, R. and R. Edwards, Quality control and preprocessing of metagenomic datasets. Bioinformatics, 2011. 27(6): p. 863-4.

16.Ewels, P., et al., MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics (Oxford, England), 2016. 32(19): p. 3047-3048.

17.Langmead, B., et al., Ultrafast and memory-efficient alignment of short DNA
sequences to the human genome. Genome Biology, 2009. 10(3): p. R25.

18. Fromm, B., et al., *A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome*. Annu Rev Genet, 2015. 49: p. 213-42.

19. Robinson, M. D., D. J. McCarthy, and G. K. Smyth, *edgeR: a Bioconductor package for differential expression analysis of digital gene expression data*. Bioinformatics, 2010. 26(1): p. 139-40.

20. Leidinger, P., et al., *A blood based 12-miRNA signature of Alzheimer disease patients*. Genome Biol, 2013. 14(7): p. R78.

21. Huang da, W., B. T. Sherman, and R. A. Lempicki, *Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources*. Nat Protoc, 2009. 4(1): p. 44-57.

22. Kanehisa, M. and S. Goto, *KEGG: Kyoto Encyclopedia of Genes and Genomes*. Nucleic Acids Research, 2000. 28(1): p. 27-30.

23. Folstein, M. F., S. E. Folstein, and P. R. McHugh, “*Mini-mental state*”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975. 12(3): p. 189-98.

24. Mengel-From, J., et al., *Circulating, Cell-Free Micro-RNA Profiles Reflect Discordant Development of Dementia in Monozygotic Twins*. J Alzheimers Dis, 2018. 63(2): p. 591-601.

25. Heneka, M. T., D. T. Golenbock, and E. Latz, *Innate immunity in Alzheimer’s disease*. Nat Immunol, 2015. 16(3): p. 229-36.

26. Roe, C. M., et al., *Alzheimer disease and cancer*. Neurology, 2005. 64(5): p. 895-8.

27. Behrens, M. I., C. Lendon, and C. M. Roe, *A common biological mechanism in
cancer and Alzheimer’s disease? Current Alzheimer research, 2009. 6(3): p. 196–204.

28. Holohan, K. N., et al., Functional microRNAs in Alzheimer’s disease and cancer: differential regulation of common mechanisms and pathways. Frontiers in Genetics, 2012. 3: p. 323.

29. Zhao, C., et al., Overexpression of miR-15b-5p promotes gastric cancer metastasis by regulating PAQR3. Oncol Rep, 2017. 38(1): p. 352–358.

30. Satoh, J.-i., Y. Kino, and S. Niida, MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer’s Disease from Public Data. Biomarker Insights, 2015. 10: p. 21–31.

Figures
Figure 1

Replicated significant miRNAs identified in current study (AIBL cohort) in an independent cohort (Leidinger et al., 2020). The table shows the log2 fold change and the p-values for two selected miRNAs: hsa-miR-15b-5p and hsa-miR-146b-5p. The changes are significant with p-values of 0.025 and 0.032 for hsa-miR-15b-5p, and 0.036 and 0.040 for hsa-miR-146b-5p in the original and replication cohorts, respectively.